Implications of heterogeneity in multiple myeloma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  De Mel, Sanjay ^a   Lim, Su Hong ^a   Tung, Moon Ley ^a   Chng, Wee Joo ^a,b,c  

^a Department of Haematology Oncology National University Cancer Institute of Singapore ^*  (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BRCA2 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CYCLIN D1; CYCLIN D3; HISTONE ACETYLTRANSFERASE; HISTONE DEMETHYLASE; IMMUNOGLOBULIN HEAVY CHAIN; K RAS PROTEIN; OSTEOGENIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

CANCER RECURRENCE; CANCER RESISTANCE; CELL DIFFERENTIATION; CHROMOSOME 13; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME LOSS; CHROMOSOME NUMBER; CHROMOSOME TRANSLOCATION; CLONAL EVOLUTION; COLONY FORMATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ACTIVITY; GENE CLUSTER; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC HETEROGENEITY; HUMAN; INDEL MUTATION; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL; PLOIDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; B LYMPHOCYTE; CHROMOSOME ABERRATION; GENETICS; MUTATION; PATHOLOGY;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CHROMOSOME ABERRATIONS; GENETIC HETEROGENEITY; HUMANS; MULTIPLE MYELOMA; MUTATION; TRANSLOCATION, GENETIC;

EID: 84904635505     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/232546     Document Type: Review

References (89)

1. Kyle R. A., Rajkumar S. V., Multiple myeloma. Blood 2008 111 6 2962 2972 2-s2.0-42449114035 10.1182/blood-2007-10-078022
2. Weiss B. M., Abadie J., Verma P., Howard R. S., Kuehl W. M., A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009 113 22 5418 5422 2-s2.0-67049114114 10.1182/blood-2008-12-195008
3. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009 113 22 5412 5417 2-s2.0-67049162188 10.1182/blood-2008-12-194241
4. Morgan G. J., Walker B. A., Davies F. E., The genetic architecture of multiple myeloma. Nature Reviews Cancer 2012 12 5 335 348 2-s2.0-84860219443 10.1038/nrc3257
5. Ocio E. M., Richardson P. G., Rajkumar S. V., New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014 28 525 542
6. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P. L., Chesi M., Davies F. E., Drach J., Greipp P. R., Kirsch I. R., Kuehl W. M., Hernandez J. M., Minvielle S., Pilarski L. M., Shaughnessy J. D. Jr., Stewart A. K., Avet-Loiseau H., Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research 2004 64 4 1546 1558 2-s2.0-10744223381 10.1158/0008-5472.CAN-03-2876 (Pubitemid 38235629)
7. Chng W. J., van Wier S. A., Ahmann G. J., Winkler J. M., Jalal S. M., Bergsagel P. L., Chesi M., Trendle M. C., Oken M. M., Blood E., Henderson K., Santana-Dávila R., Kyle R. A., Gertz M. A., Lacy M. Q., Dispenzieri A., Greipp P. R., Fonseca R., A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005 106 6 2156 2161 2-s2.0-24744434736 10.1182/blood-2005-02-0761 (Pubitemid 41291733)
8. Fonseca R., Bergsagel P. L., Drach J., Shaughnessy J., Gutierrez N., Stewart A. K., Morgan G., Van Ness B., Chesi M., Minvielle S., Neri A., Barlogie B., Kuehl W. M., Liebisch P., Davies F., Chen-Kiang S., Durie B. G. M., Carrasco R., Sezer O., Reiman T., Pilarski L., Avet-Loiseau H., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009 23 12 2210 2221 2-s2.0-74049162897 10.1038/leu.2009.174
9. O'Neal J., Gao F., Hassan A., Monahan R., Barrios S., Lee I., Chng W. J., Vij R., Tomasson M. H., Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Experimental Hematology 2009 37 2 234 244 2-s2.0-58149195202 10.1016/j.exphem.2008.10.014
10. Roccaro A. M., Sacco A., Thompson B., Leleu X., Azab A. K., Azab F., Runnels J., Jia X., Ngo H. T., Melhem M. R., Lin C. P., Ribatti D., Rollins B. J., Witzig T. E., Anderson K. C., Ghobrial I. M., MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009 113 26 6669 6680 2-s2.0-69249225706 10.1182/blood-2009-01-198408
11. Zhan F., Sawyer J., Gupta S., Elevated expression of CKS1B at 1q21 is highly correlated with short survival in myeloma. Blood 2004 104, abstract 77
12. Willis T. G., Zalcberg I. R., Coignet L. J. A., Wlodarska I., Stul M., Jadayel D. M., Bastard C., Treleaven J. G., Catovsky D., Silva M. L. M., Dyer M. J. S., Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998 91 6 1873 1881 2-s2.0-0032520975 (Pubitemid 28185487)
13. Craig R. W., Jabs E. W., Zhou P., Kozopas K. M., Hawkins A. L., Rochelle J. M., Seldin M. F., Griffin C. A., Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 1994 23 2 457 463 2-s2.0-0027957089 10.1006/geno.1994.1523 (Pubitemid 24308268)
14. Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J., Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. American Journal of Pathology 2004 165 1 71 81 2-s2.0-3042683879 (Pubitemid 38821815)
15. Dyomin V. G., Palanisamy N., Lloyd K. O., Dyomina K., Jhanwar S. C., Houldsworth J., Chaganti R. S. K., MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 2000 95 8 2666 2671 2-s2.0-0034655650 (Pubitemid 30210548)
16. Chng W. J., Gertz M. A., Chung T.-H., Van Wier S., Keats J. J., Baker A., Bergsagel P. L., Carpten J., Fonseca R., Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010 24 4 833 842 2-s2.0-77950949924 10.1038/leu.2010.21
17. Boyd K. D., Ross F. M., Tapper W. J., Chiecchio L., Dagrada G., Konn Z. J., Gonzalez D., Walker B. A., Hockley S. L., Wardell C. P., Gregory W. M., Anthony Child J., Jackson G. H., Davies F. E., Morgan G. J., The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes and Cancer 2011 50 10 765 774 2-s2.0-80051553676 10.1002/gcc.20899
18. Lodé L., Eveillard M., Trichet V., Soussi T., Wuillème S., Richebourg S., Magrangeas F., Ifrah N., Campion L., Traullé C., Guilhot F., Caillot D., Marit G., Mathiot C., Facon T., Attal M., Harousseau J.-L., Moreau P., Minvielle S., Avet-Loiseau H., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010 95 11 1973 1976 2-s2.0-78149246124 10.3324/haematol.2010.023697
19. Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J.-L., Bataille R., Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001 98 10 3082 3086 2-s2.0-0035892119 10.1182/blood.V98.10.3082
20. Chng W.-J., Huang G. F., Chung T. H., Ng S. B., Gonzalez-Paz N., Troska-Price T., Mulligan G., Chesi M., Bergsagel P. L., Fonseca R., Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011 25 6 1026 1035 2-s2.0-79958095463 10.1038/leu.2011.53
21. Affer M., Chesi M., Chen W. D., Promiscuous rearrangements of the MYC locus hijack enhancers and super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014
22. Chng W. J., Gonzalez-Paz N., Price-Troska T., Jacobus S., Rajkumar S. V., Oken M. M., Kyle R. A., Henderson K. J., Van Wier S., Greipp P., Van Ness B., Fonseca R., Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008 22 12 2280 2284 2-s2.0-57849129292 10.1038/leu.2008.142
23. Chng W. J., Glebov O., Bergsagel P. L., Kuehl W. M., Genetic events in the pathogenesis of multiple myeloma. Best Practice and Research: Clinical Haematology 2007 20 4 571 596 2-s2.0-36749027626 10.1016/j.beha.2007.08.004 (Pubitemid 350215376)
24. Lohr J. G., Stojanov P., Carter S. L., Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014 25 91 101
25. Rasmussen T., Kuehl M., Lodahl M., Johnsen H. E., Dahl I. M. S., Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005 105 1 317 323 2-s2.0-11144235574 10.1182/blood-2004-03-0833 (Pubitemid 40053099)
26. Chng W. J., Price-Troska T., Gonzalez-Paz N., Van Wier S., Jacobus S., Blood E., Henderson K., Oken M., Van Ness B., Greipp P., Rajkumar S. V., Fonseca R., Clinical significance of TP53 mutation in myeloma [13]. Leukemia 2007 21 3 582 584 2-s2.0-33847224187 10.1038/sj.leu.2404524
27. Bergsagel P. L., Kuehl W. M., Zhan F., Sawyer J., Barlogie B., Shaughnessy J. Jr., Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005 106 1 296 303 2-s2.0-22044440425 10.1182/blood-2005-01-0034 (Pubitemid 40967205)
28. Fonseca R., Debes-Marun C. S., Picken E. B., Dewald G. W., Bryant S. C., Winkler J. M., Blood E., Oken M. M., Santana-Dávila R., González-Paz N., Kyle R. A., Gertz M. A., Dispenzieri A., Lacy M. Q., Greipp P. R., The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003 102 7 2562 2567 2-s2.0-0141481984 10.1182/blood-2003-02-0493 (Pubitemid 37193596)
29. Keats J. J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L. A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J., Stewart A. K., Carpten J., Bergsagel P. L., Promiscuous mutations activate the noncanonical NF- κ B pathway in multiple myeloma. Cancer Cell 2007 12 2 131 144 2-s2.0-34547660308 10.1016/j.ccr.2007.07.003 (Pubitemid 47208626)
30. Annunziata C. M., Davis R. E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., Dave S., Hurt E. M., Tan B., Zhao H., Stephens O., Santra M., Williams D. R., Dang L., Barlogie B., Shaughnessy J. D. Jr., Kuehl W. M., Staudt L. M., Frequent engagement of the classical and alternative NF- κ B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007 12 2 115 130 2-s2.0-34547562418 10.1016/j.ccr.2007.07. 004 (Pubitemid 47199123)
31. Chapman M. A., Lawrence M. S., Keats J. J., Cibulskis K., Sougnez C., Schinzel A. C., Harview C. L., Brunet J.-P., Ahmann G. J., Adli M., Anderson K. C., Ardlie K. G., Auclair D., Baker A., Bergsagel P. L., Bernstein B. E., Drier Y., Fonseca R., Gabriel S. B., Hofmeister C. C., Jagannath S., Jakubowiak A. J., Krishnan A., Levy J., Liefeld T., Lonial S., Mahan S., Mfuko B., Monti S., Perkins L. M., Onofrio R., Pugh T. J., Rajkumar S. V., Ramos A. H., Siegel D. S., Sivachenko A., Stewart A. K., Trudel S., Vij R., Voet D., Winckler W., Zimmerman T., Carpten J., Trent J., Hahn W. C., Garraway L. A., Meyerson M., Lander E. S., Getz G., Golub T. R., Initial genome sequencing and analysis of multiple myeloma. Nature 2011 471 7339 467 472 2-s2.0-79951494668 10.1038/nature09837
32. Munshi N. C., Anderson K. C., Bergsagel P. L., Shaughnessy J., Palumbo A., Durie B., Fonseca R., Stewart A. K., Harousseau J.-L., Dimopoulos M., Jagannath S., Hajek R., Sezer O., Kyle R., Sonneveld P., Cavo M., Rajkumar S. V., San Miguel J., Crowley J., Avet-Loiseau H., Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011 117 18 4696 4700 2-s2.0-79956039754 10.1182/blood-2010-10-300970
33. Avet-Loiseau H., Role of genetics in prognostication in myeloma. Best Practice and Research: Clinical Haematology 2007 20 4 625 635 2-s2.0-36849014859 10.1016/j.beha.2007.08.005 (Pubitemid 350225352)
34. Hanamura I., Stewart J. P., Huang Y., Zhan F., Santra M., Sawyer J. R., Hollmig K., Zangarri M., Pineda-Roman M., Van Rhee F., Cavallo F., Burington B., Crowley J., Tricot G., Barlogie B., Shaughnessy J. D. Jr., Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006 108 5 1724 1732 2-s2.0-33748196399 10.1182/blood-2006-03-009910 (Pubitemid 44316143)
35. Fonseca R., van Wier S. A., Chng W. J., Ketterling R., Lacy M. Q., Dispenzieri A., Bergsagel P. L., Rajkumar S. V., Greipp P. R., Litzow M. R., Price-Troska T., Henderson K. J., Ahmann G. J., Gertz M. A., Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006 20 11 2034 2040 2-s2.0-33750327901 10.1038/sj.leu.2404403 (Pubitemid 44614894)
36. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., Leyvraz S., Michallet M., Yakoub-Agha I., Garderet L., Marit G., Michaux L., Voillat L., Renaud M., Grosbois B., Guillerm G., Benboubker L., Monconduit M., Thieblemont C., Casassus P., Caillot D., Stoppa A.-M., Sotto J.-J., Wetterwald M., Dumontet C., Fuzibet J.-G., Azais I., Dorvaux V., Zandecki M., Bataille R., Minvielle S., Harousseau J.-L., Facon T., Mathiot C., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007 109 8 3489 3495 2-s2.0-33847378314 10.1182/blood-2006-08-040410 (Pubitemid 46572539)
37. Avet-Loiseau H., Malard F., Campion L., Magrangeas F., Sebban C., Lioure B., Decaux O., Lamy T., Legros L., Fuzibet J.-G., Michallet M., Corront B., Lenain P., Hulin C., Mathiot C., Attal M., Facon T., Harousseau J.-L., Minvielle S., Moreau P., Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011 117 6 2009 2011 2-s2.0-79951504474 10.1182/blood-2010-07-295105
38. Boyd K. D., Ross F. M., Chiecchio L., Dagrada G. P., Konn Z. J., Tapper W. J., Walker B. A., Wardell C. P., Gregory W. M., Szubert A. J., Bell S. E., Child J. A., Jackson G. H., Davies F. E., Morgan G. J., A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012 26 2 349 355 2-s2.0-84856706335 10.1038/leu.2011.204
39. Fonseca R., Blood E., Rue M., Harrington D., Oken M. M., Kyle R. A., Dewald G. W., Van Ness B., Van Wier S. A., Henderson K. J., Bailey R. J., Greipp P. R., Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003 101 11 4569 4575 2-s2.0-0038142356 10.1182/blood-2002-10- 3017 (Pubitemid 36857829)
40. Hebraud B., Leleu X., Lauwers-Cances V., Roussel M., Caillot D., Marit G., Karlin L., Hulin C., Gentil C., Guilhot F., Garderet L., Lamy T., Brechignac S., Pegourie B., Jaubert J., Dib M., Stoppa A.-M., Sebban C., Fohrer C., Fontan J., Fruchart C., Macro M., Orsini-Piocelle F., Lepeu G., Sohn C., Corre J., Facon T., Moreau P., Attal M., Avet-Loiseau H., Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014 28 675 679 2-s2.0-84881422651 10.1038/leu.2013.225
41. Boyd K. D., Ross F. M., Walker B. A., Wardell C. P., Tapper W. J., Chiecchio L., Dagrada G., Konn Z. J., Gregory W. M., Jackson G. H., Child J. A., Davies F. E., Morgan G. J., Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clinical Cancer Research 2011 17 24 7776 7784 2-s2.0-84055212016 10.1158/1078-0432.CCR-11-1791
42. Andrulis M., Lehners N., Capper D., Penzel R., Heining C., Huellein J., Zenz T., von Deimling A., Schirmacher P., Ho A. D., Goldschmidt H., Neben K., Raab M. S., Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discovery 2013 3 8 862 869 2-s2.0-84881490568 10.1158/2159-8290.CD-13-0014
43. Mulligan G., Lichter D. I., di Bacco A., Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014 123 632 639
44. Ludwig H., Bolejack V., Crowley J., Bladé J., San Miguel J., Kyle R. A., Rajkumar S. V., Shimizu K., Turesson I., Westin J., Sonneveld P., Cavo M., Boccadoro M., Palumbo A., Tosi P., Harousseau J.-L., Attal M., Barlogie B., Stewart A. K., Durie B., Survival and years of life lost in different age cohorts of patients with multiple myeloma. Journal of Clinical Oncology 2010 28 9 1599 1605 2-s2.0-77951923656 10.1200/JCO.2009.25.2114
45. Avet-Loiseau H., Attal M., Campion L., Caillot D., Hulin C., Marit G., Stoppa A.-M., Voillat L., Wetterwald M., Pegourie B., Voog E., Tiab M., Banos A., Jaubert J., Bouscary D., Macro M., Kolb B., Traulle C., Mathiot C., Magrangeas F., Minvielle S., Facon T., Moreau P., Long-term analysis of the ifm 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. Journal of Clinical Oncology 2012 30 16 1949 1952 2-s2.0-84863919796 10.1200/JCO.2011.36.5726
46. Durie B. G. M., Salmon S. E., A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 36 3 842 854 2-s2.0-0016804136
47. Greipp P. R., Miguel J. S., Dune B. G. M., Crowley J. J., Barlogie B., Bladé J., Boccadoro M., Child J. A., Harousseau J.-L., Kyle R. A., Lahuerta J. J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., Westin J., International staging system for multiple myeloma. Journal of Clinical Oncology 2005 23 15 3412 3420 2-s2.0-20644460600 10.1200/JCO.2005.04.242
48. Avet-Loiseau H., Durie B. G. M., Cavo M., Attal M., Gutierrez N., Haessler J., Goldschmidt H., Hajek R., Lee J. H., Sezer O., Barlogie B., Crowley J., Fonseca R., Testoni N., Ross F., Rajkumar S. V., Sonneveld P., Lahuerta J., Moreau P., Morgan G., Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013 27 3 711 717 2-s2.0-84875209671 10.1038/leu.2012.282
49. Shaughnessy J. D. Jr., Barlogie B., Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biology of Blood and Marrow Transplantation 2006 12 1 77 80 2-s2.0-29844450880 10.1016/j.bbmt.2005.10.002 (Pubitemid 43034124)
50. Decaux O., Lodé L., Magrangeas F., Charbonnel C., Gouraud W., Jézéquel P., Attal M., Harousseau J.-L., Moreau P., Bataille R., Campion L., Avet-Loiseau H., Minvielle S., Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. Journal of Clinical Oncology 2008 26 29 4798 4805 2-s2.0-54249092519 10.1200/JCO.2007.13.8545
51. Chng W. J., Braggio E., Mulligan G., Bryant B., Remstein E., Valdez R., Dogan A., Fonseca R., The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008 111 3 1603 1609 2-s2.0-38949203768 10.1182/blood-2007-06-097774 (Pubitemid 351213451)
52. Dickens N. J., Walker B. A., Leone P. E., Johnson D. C., Brito J. L., Zeisig A., Jenner M. W., Boyd K. D., Gonzalez D., Gregory W. M., Ross F. M., Davies F. E., Morgan G. J., Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clinical Cancer Research 2010 16 6 1856 1864 2-s2.0-77949686098 10.1158/1078-0432.CCR-09-2831
53. Moreaux J., Klein B., Bataille R., Descamps G., Maïga S., Hose D., Goldschmidt H., Jauch A., Rème T., Jourdan M., Amiot M., Pellat-Deceunynck C., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011 96 4 574 582 2-s2.0-79953892192 10.3324/haematol.2010.033456
54. Hose D., Rème T., Hielscher T., Moreaux J., Messner T., Seckinger A., Benner A., Shaughnessy J. D. Jr., Barlogie B., Zhou Y., Hillengass J., Bertsch U., Neben K., Möhler T., Rossi J. F., Jauch A., Klein B., Goldschmidt H., Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011 96 1 87 95 2-s2.0-78650981539 10.3324/haematol.2010.030296
55. Kuiper R., Broyl A., De Knegt Y., Van Vliet M. H., Van Beers E. H., Van Der Holt B., El Jarari L., Mulligan G., Gregory W., Morgan G., Goldschmidt H., Lokhorst H. M., Van Duin M., Sonneveld P., A gene expression signature for high-risk multiple myeloma. Leukemia 2012 26 11 2406 2413 2-s2.0-84869085660 10.1038/leu.2012.127
56. Chung T.-H., Mulligan G., Fonseca R., Chng W. J., A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS ONE 2013 8 6 2-s2.0-84879266916 10.1371/journal.pone.0066361 e66361
57. Chng W. J., Dispenzieri A., Chim C. S., IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014 28 269 277
58. Yates L. R., Campbell P. J., Evolution of the cancer genome. Nature Reviews Genetics 2012 13 11 795 806 2-s2.0-84867744264 10.1038/nrg3317
59. Bolli N., Avet-Loiseau H., Wedge D. C., Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications 2014 5, article 2997
60. Keats J. J., Chesi M., Egan J. B., Garbitt V. M., Palmer S. E., Braggio E., Van Wier S., Blackburn P. R., Baker A. S., Dispenzieri A., Kumar S., Rajkumar S. V., Carpten J. D., Barrett M., Fonseca R., Stewart A. K., Bergsagel P. L., Clonal competition with alternating dominance in multiple myeloma. Blood 2012 120 5 1067 1076 2-s2.0-84861532638 10.1182/blood-2012-01-405985
61. Egan J. B., Shi C.-X., Tembe W., Christoforides A., Kurdoglu A., Sinari S., Middha S., Asmann Y., Schmidt J., Braggio E., Keats J. J., Fonseca R., Bergsagel P. L., Craig D. W., Carpten J. D., Stewart A. K., Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012 120 5 1060 1066 2-s2.0-84864561961 10.1182/blood-2012-01-405977
62. Tubio J. M. C., Estivill X., Cancer: when catastrophe strikes a cell. Nature 2011 470 7335 476 477 2-s2.0-79952120598 10.1038/470476a
63. Magrangeas F., Avet-Loiseau H., Munshi N. C., Minvielle S., Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011 118 3 675 678 2-s2.0-79960693423 10.1182/blood-2011-03-344069
64. Walker B. A., Wardell C. P., Melchor L., Brioli A., Johnson D. C., Kaiser M. F., Mirabella F., Lopez-Corral L., Humphray S., Murray L., Ross M., Bentley D., Gutiérrez N. C., Garcia-Sanz R., San Miguel J., Davies F. E., Gonzalez D., Morgan G. J., Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014 28 384 390 2-s2.0-84880184173 10.1038/leu.2013.199
65. Chesi M., Robbiani D. F., Sebag M., Chng W. J., Affer M., Tiedemann R., Valdez R., Palmer S. E., Haas S. S., Stewart A. K., Fonseca R., Kremer R., Cattoretti G., Bergsagel P. L., AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008 13 2 167 180 2-s2.0-38549131395 10.1016/j.ccr.2008.01.007 (Pubitemid 351163163)
66. Drewinko B., Alexanian R., Boyer H., Barlogie B., Rubinow S. I., The growth fraction of human myeloma cells. Blood 1981 57 2 333 338 2-s2.0-0019378791 (Pubitemid 11174896)
67. Hamburger A., Salmon S. S., Primary bioassay of human myeloma stem cells. Journal of Clinical Investigation 1977 60 4 846 854 2-s2.0-0017718628 (Pubitemid 8208477)
68. Bakkus M. H. C., van Riet I., van Camp B., Thielemans K., Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. British Journal of Haematology 1994 87 1 68 74 2-s2.0-0028246112 (Pubitemid 24207001)
69. Pilarski L. M., Belch A. R., Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34+ hematopoietic progenitors. Clinical Cancer Research 2002 8 10 3198 3204 2-s2.0-0036794974 (Pubitemid 35155031)
70. Matsui W., Huff C. A., Wang Q., Malehorn M. T., Barber J., Tanhehco Y., Smith B. D., Civin C. I., Jones R. J., Characterization of clonogenic multiple myeloma cells. Blood 2004 103 6 2332 2336 2-s2.0-1542283717 10.1182/blood-2003- 09-3064 (Pubitemid 38326254)
71. Epstein J., Myeloma stem cell phenotype: implications for treatment. Hematology/Oncology Clinics of North America 1997 11 1 43 49 2-s2.0-0030934954 10.1016/S0889-8588(05)70414-7 (Pubitemid 27147745)
72. Gottesman M. M., Fojo T., Bates S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002 2 1 48 58 2-s2.0-0036364467 (Pubitemid 37328807)
73. Reghunathan R., Bi C., Liu S. C., Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival. Oncotarget 2013 4 1230 1240
74. Rasmussen T., Jensen L., Johnsen H. E., The clonal hierachy in multiple myeloma. Acta Oncologica 2000 39 7 765 770
75. Boucher K., Parquet N., Widen R., Shain K., Baz R., Alsina M., Koomen J., Anasetti C., Dalton W., Perez L. E., Stemness of B-cell progenitors in multiple myeloma bone marrow. Clinical Cancer Research 2012 18 22 6155 6168 2-s2.0-84869209212 10.1158/1078-0432.CCR-12-0531
76. Chaidos A., Barnes C. P., Cowan G., May P. C., Melo V., Hatjiharissi E., Papaioannou M., Harrington H., Doolittle H., Terpos E., Dimopoulos M., Abdalla S., Yarranton H., Naresh K., Foroni L., Reid A., Rahemtulla A., Stumpf M., Roberts I., Karadimitris A., Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013 121 2 318 328 2-s2.0-84872345792 10.1182/blood-2012-06- 436220
77. Leung-Hagesteijn C., Erdmann N., Cheung G., Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013 24 289 304
78. Yang Y., Shi J., Tolomelli G., RARalpha2 expression confers myeloma stem cell features. Blood 2013 122 1437 1447
79. Kassambara A., Hose D., Moreaux J., Rème T., Torrent J., Rossi J. F., Goldschmidt H., Klein B., Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS ONE 2012 7 7 2-s2.0-84864458523 10.1371/journal.pone.0042161 e42161
80. Paiva B., Vidriales M.-B., Cerveró J., Mateo G., Pérez J. J., Montalbán M. A., Sureda A., Montejano L., Gutiérrez N. C., De Coca A. G., De Las Heras N., Mateos M. V., López-Berges M. C., García-Boyero R., Galende J., Hernández J., Palomera L., Carrera D., Martínez R., De La Rubia J., Martín A., Bladé J., Lahuerta J. J., Orfao A., San Miguel J. F., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008 112 10 4017 4023 2-s2.0-59449099316 10.1182/blood-2008-05-159624
81. Rawstron A. C., Child J. A., de Tute R. M., Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology 2013 31 2540 2547
82. Sarasquete M. E., García-Sanz R., González D., Martínez J., Mateo G., Martínez P., Ribera J. M., Hernández J. M., Lahuerta J. J., Orfão A., González M., San Miguel J. F., Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005 90 10 1365 1372 2-s2.0-27144546033 (Pubitemid 41503652)
83. Zamagni E., Patriarca F., Nanni C., Zannetti B., Englaro E., Pezzi A., Tacchetti P., Buttignol S., Perrone G., Brioli A., Pantani L., Terragna C., Carobolante F., Baccarani M., Fanin R., Fanti S., Cavo M., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011 118 23 5989 5995 2-s2.0-82955189267 10.1182/blood-2011-06-361386
84. Matsui W., Wang Q., Barber J. P., Brennan S., Smith B. D., Borrello I., McNiece I., Lin L., Ambinder R. F., Peacock C., Watkins D. N., Huff C. A., Jones R. J., Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research 2008 68 1 190 197 2-s2.0-38549132452 10.1158/0008-5472.CAN-07-3096 (Pubitemid 351380120)
85. Peacock C. D., Wang Q., Gesell G. S., Corcoran-Schwartz I. M., Jones E., Kim J., Devereux W. L., Rhodes J. T., Huff C. A., Beachy P. A., Watkins D. N., Matsui W., Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 2007 104 10 4048 4053 2-s2.0-34247192972 10.1073/pnas. 0611682104 (Pubitemid 47181576)
86. Chiron D., Maïga S., Descamps G., Moreau P., Le Gouill S., Marionneau S., Ouiller T., Moreaux J., Klein B., Bataille R., Amiot M., Pellat-Deceunynck C., Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells, Molecules, and Diseases 2012 48 4 247 253 2-s2.0-84858796264 10.1016/j.bcmd.2012.01.006
87. Brennan S. K., Wang Q., Tressler R., Harley C., Go N., Bassett E., Huff C. A., Jones R. J., Matsui W., Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent Mechanisms. PLoS ONE 2010 5 9 2-s2.0-77958584577 10.1371/journal.pone.0012487 e12487
88. Björkstrand B., Ljungman P., Svensson H., Hermans J., Alegre A., Apperley J., Bladé J., Carlson K., Cavo M., Ferrant A., Goldstone A. H., De Laurenzi A., Majolino I., Marcus R., Prentice H. G., Remes K., Samson D., Sureda A., Verdonck L. F., Volin L., Gahrton G., Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996 88 12 4711 4718 2-s2.0-10544228954 (Pubitemid 26419156)
89. Swift B. E., Williams B. A., Kosaka Y., Wang X.-H., Medin J. A., Viswanathan S., Martinez-Lopez J., Keating A., Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012 97 7 1020 1028 2-s2.0-84863908333 10.3324/haematol.2011.054254